Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2002

View Archived Issues

Human Genome Sciences compounds advance into the clinic in second quarter

Apomine enters proof-of-principle trial in osteoporosis

Enrollment complete in tecadenoson phase III trial

Third-generation beta1/alpha-adrenoceptor blocker with hypotensive and bradycardic effects

Bifunctional fusion protein targeting breast cancer cells active in murine model

Safety and efficacy demonstrated for phVEGF2 in dose-escalating phase I/II trial

Liposomal TOP-53 may be associated with improved tolerance

Manufacturing approval obtained for Onoact

AstraZeneca presents new ERbeta ligands for AD and other disorders

Sepracor scientists identify new opioid and other GPCR ligands

Antidiabetic glucokinase activators identified at Roche

ZymoGenetics signs IL-13 receptor license agreement with Wyeth

Novel PPARalpha receptor agonists in the GSK pipeline

Roche scientists describe novel COX-2 inhibitors and their use

Major European launch for Otsuka antithrombotic agent

Carboxylic acid-based PPAR agonists in development at Kyorin

HDAC-inhibitory hydroxamates recently described in Roche patent

Genset licenses rights for Chlamydia genomic sequences to Ricerca

DNA minor groove-binding antitumor agent with potential in refractory tumors

Mitsubishi Chemical invests in IC-Vec for nonviral cancer gene therapy

GlaxoSmithKline to collaborate with elbion on PDE4 inhibitor development

Vernalis and Roche update obesity collaboration progress

Xyotax enters phase III evaluation in ovarian cancer

Roche licenses Alzheimer's compounds from Memory

Exhale licenses hyaluronic acid for prevention of group A streptococcal pharyngitis

Arixtra launched in Germany for preventing VTEs

Potential new treatment for cystic fibrosis designated an orphan drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 11, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...